These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Cholesterol absorption as a target for the treatment of hypercholesterolemia]. Bitzur R; Cohen H; Harats D Harefuah; 2006 Nov; 145(11):831-5, 861, 860. PubMed ID: 17183957 [TBL] [Abstract][Full Text] [Related]
4. [New results in the management of hypercholesterolemia]. Sármán B Orv Hetil; 2005 Sep; 146(39):1999-2004. PubMed ID: 16265867 [TBL] [Abstract][Full Text] [Related]
5. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422 [TBL] [Abstract][Full Text] [Related]
6. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Daskalopoulou SS; Mikhailidis DP Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035 [TBL] [Abstract][Full Text] [Related]
7. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients]. Tachibana E; Watanabe I; Nagao K; Kanmatsuse K J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271 [TBL] [Abstract][Full Text] [Related]
8. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082 [TBL] [Abstract][Full Text] [Related]
9. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future? Kastelein JJ Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010 [TBL] [Abstract][Full Text] [Related]
10. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245 [TBL] [Abstract][Full Text] [Related]
11. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Bruckert E; Giral P; Tellier P Circulation; 2003 Jul; 107(25):3124-8. PubMed ID: 12835406 [No Abstract] [Full Text] [Related]
12. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E; J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343 [TBL] [Abstract][Full Text] [Related]
13. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Hou R; Goldberg AC Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513 [TBL] [Abstract][Full Text] [Related]
14. Novel agents to manage dyslipidemias and impact atherosclerosis. Nachimuthu S; Raggi P Cardiovasc Hematol Disord Drug Targets; 2006 Sep; 6(3):209-17. PubMed ID: 17017903 [TBL] [Abstract][Full Text] [Related]
15. Achieving optimal lipid goals in patients with coronary artery disease. Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526 [TBL] [Abstract][Full Text] [Related]
16. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin. Sampalis JS; Bissonnette S; Habib R; Boukas S; Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579 [TBL] [Abstract][Full Text] [Related]
17. The treatment of dyslipidemia--what's left in the pipeline? Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209 [TBL] [Abstract][Full Text] [Related]
18. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E; Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231 [TBL] [Abstract][Full Text] [Related]
19. [Recommended LDL value far lower. How does one achieve this goal?]. Einecke D MMW Fortschr Med; 2004 Mar; 146(13):6. PubMed ID: 15219116 [No Abstract] [Full Text] [Related]